ImageneBio, Inc. Capital Expenditures
ImageneBio, Inc. (IMA) reported Capital Expenditures of $414.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2025-03-06
- ImageneBio, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-12-31 was $262.00K, a 13.42% increase year-over-year.
- ImageneBio, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- ImageneBio, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- ImageneBio, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-03-31 was $152.00K, a 360.61% increase year-over-year.
- ImageneBio, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $414.00K, a 71.07% decline from fiscal 2022.
- ImageneBio, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $1.43M, a 18.69% decline from fiscal 2021.
- ImageneBio, Inc. payments to acquire property, plant, and equipment for fiscal 2021 was $1.76M, a 129.77% increase from fiscal 2020.
- ImageneBio, Inc. payments to acquire property, plant, and equipment for fiscal 2020 was $766.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2023-12-31 | $262.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $262.00K derived: sum of 2 quarters · filed 2025-03-06 | $262.00K derived: sum of 3 quarters · filed 2025-03-06 | $414.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $152.00K 10-Q · filed 2024-11-07 | $383.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $152.00K 10-Q · filed 2024-08-08 | $383.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.51M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $152.00K 10-Q · filed 2024-05-13 | $383.00K derived: sum of 2 quarters · filed 2024-05-13 | $1.51M derived: sum of 3 quarters · filed 2024-05-13 | $1.55M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $1.36M derived: sum of 2 quarters · filed 2024-03-12 | $1.40M derived: sum of 3 quarters · filed 2024-03-12 | $1.43M 10-K · filed 2024-03-12 |
| 2022-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.17M derived: sum of 2 quarters · filed 2023-11-09 | $1.20M 10-Q · filed 2023-11-09 | $1.75M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $69.00K 10-Q · filed 2023-08-10 | $619.00K derived: sum of 3 quarters · filed 2023-08-10 | $803.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $33.00K 10-Q · filed 2023-05-15 | $583.00K derived: sum of 2 quarters · filed 2023-05-15 | $767.00K derived: sum of 3 quarters · filed 2023-05-15 | $954.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $550.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $734.00K derived: sum of 2 quarters · filed 2023-03-14 | $921.00K derived: sum of 3 quarters · filed 2023-03-14 | $1.76M 10-K · filed 2023-03-14 |
| 2021-09-30 | $184.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $371.00K derived: sum of 2 quarters · filed 2022-11-07 | $1.21M 10-Q · filed 2022-11-07 | $1.86M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $187.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.03M 10-Q · filed 2022-08-11 | $1.68M derived: sum of 3 quarters · filed 2022-08-11 | $1.68M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $839.00K 10-Q · filed 2022-05-12 | $1.49M derived: sum of 2 quarters · filed 2022-05-12 | $1.49M derived: sum of 3 quarters · filed 2022-05-12 | $1.49M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $650.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $650.00K derived: sum of 2 quarters · filed 2022-03-17 | $649.00K derived: sum of 3 quarters · filed 2022-03-17 | $766.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$1.00K derived: sum of 2 quarters · filed 2021-11-10 | $116.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $116.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $117.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |